Reply to ‘Comment on: Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab’

Abstract

Another aspect of NVG prevention is represented by treating the patients with central/hemi-CRVOs in whom ocular neovascularization already has appeared but IOP still remains within normal limits (eg, the preglaucomatous stage of NVG 2 ). In such cases we administer IVB injections, topical steroids, and cycloplegics; unless the neovascularization subsides with these treatments, we promptly apply panretinal photocoagulation that may prevent or delay any developing of the intractable sightthreatening NVG.In conclusion, we believe that at a dose of 2.5 mg injected promptly before occurrence of neovascularization and IOP elevation, IVB offers a real benefit and promise for the prevention of NVG in patients with acute central/hemi-CRVOs. Early diagnosis and treatment with bevacizumab are required in order to maintain a good visual status and a satisfactory IOP control. Conflict of interestThe authors declare no conflict of interest. Author contributionsBoth authors (DC and MC) were involved in design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript.

Integrative Analysis Identified rs907091 at the miRNA Binding Region of the IKZF3 Gene as a Potential Functional Variant for Rheumatoid Arthritis

“…It is well known that immune cells such as T and B lymphocytes are crucial in the pathogenesis and development of RA and are involved in the activation of immune cells and secretion of multiple cytokines. Furthermore, recent studies have shown that IKZF3 is associated not only with RA [49][50][51] but also with other autoimmune diseases [41,[52][53][54] .…”